Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT (EmFin-Nx)
A Multicenter, Open-Label, Factorial Design, Randomized Controlled Study to Explore the Efficacy and Safety of Finerenone and Empagliflozin, Alone or in Combination, in Delaying Renal Function Progression in High-Risk CKD Patients After Radical Nephrectomy for Renal Cell Carcinoma
Sponsor: Jinling Hospital, China
Terminated
The patient enrollment rate is proceeding too slowly
Other terminated trials from Jinling Hospital, China
A PHASE2 clinical study on Chronic Kidney Disease(CKD) and Nephrectomy, this trial is terminated or withdrawn. The trial is conducted by Jinling Hospital, China and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Mar 2025 — Jan 2026 [monthly]
Recruiting PHASE2
First recorded
Jan 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jinling Hospital, China
- Qilu Hospital of Shandong University
- The Affiliated Hospital of Xuzhou Medical University
- The First Affiliated Hospital with Nanjing Medical University
- Yantai Yuhuangding Hospital
For direct contact, visit the study record on ClinicalTrials.gov .